Good day, and welcome back to IPO Stream. This week the IPO market picks up momentum with three deals spanning energy equipment, psychedelic pharmaceuticals, and a healthcare/defense SPAC.

Scheduling note: Brookline Capital Acquisition Corp. II is back on the calendar after being postponed on February 26, 2026 amid a sharp NASDAQ sell-off of 250+ points. The unit structure was revised and the deal is now re-launched for this week.

Here's your week at a glance:

This guide from Deel breaks down how to build one global hiring system. You’ll learn about assessment frameworks that scale, how to do headcount planning across regions, and even intake processes that work everywhere. As HR pros know, hiring in one country is hard enough. So let this free global hiring guide give you the tools you need to avoid global hiring headaches.

Download the free guide today

HMH Holding is a Houston, Texas-based global provider of highly engineered, mission-critical drilling equipment, services, and systems for the oil and gas industry. The company was formed on October 1, 2021 through the combination of Baker Hughes' Subsea and Surface Drilling Systems (SDS) division and Akastor ASA's wholly owned subsidiary MHWirth AS. Prior to the IPO, Baker Hughes and Akastor each hold a 50% stake.

The company carries over 125 years of combined operational history under its brands: Hydril Pressure Control, VetcoGray, Wirth, and Maritime Hydraulics. HMH operates in 16 countries with sales in 60+ countries, employing 2,068 people globally, with major hubs in Houston, Texas and Kristiansand, Norway.

Revenue comes from three channels: Projects & Products (new drilling equipment packages); Aftermarket Services (maintenance, repair, spare parts, certification); and OEM/Manufacturers (supply to shipyards and capital equipment makers). The Aftermarket Services segment is recurring and high-margin.

HMH is the week's standout deal - the most credible IPO on this calendar and arguably one of the more interesting energy-sector listings in several quarters. It is profitable, globally-scaled, backed by reputable owners, and priced at a fair multiple relative to peers.

The fact that ~64% of proceeds repay shareholder loans to Baker Hughes and Akastor is something investors must understand clearly - this is not growth capital. That said, the business is cash-generative and the aftermarket revenue mix is the quality signal.

The offshore drilling equipment sector is not flashy, but in an environment where energy security is top of mind, it is the kind of infrastructure play that institutional allocators take seriously.

Optimi Health Ltd. is a Canadian Good Manufacturing Practices (GMP)-compliant pharmaceutical manufacturer, licensed by Health Canada for the production of controlled substances: psilocybin derived from botanical sources and MDMA. The company operates through its subsidiary Optimi Labs from two 10,000-square-foot production facilities in Princeton, British Columbia.

IMPORTANT: This is a NASDAQ uplisting, not a traditional IPO. Optimi's shares already trade on the Canadian Securities Exchange (CSE: OPTI), Frankfurt Stock Exchange (FSE: 8BN), and OTCQX Market (OPTHF). The company is conducting a US public offering concurrent with a NASDAQ listing application, including a 1-for-30 reverse share split.

Critical investor distinction: Optimi is a pharmaceutical-grade API manufacturer and supplier - it is NOT a clinical trial sponsor. Phase 2 trials referenced in the prospectus are conducted by third-party researchers; Optimi supplies the controlled-substance API to those operators. Optimi's commercial prospects depend on regulatory milestones it does not directly control.

Optimi occupies a genuinely unique regulatory space - one of very few companies globally authorized to manufacture pharmaceutical-grade psilocybin and MDMA at scale. For investors in the psychedelic therapeutics sector, Optimi is one of the purest-play infrastructure bets available publicly.

That said, the risk profile is substantial. Revenue is minimal (under C$500K for the full fiscal year), losses are ongoing, the company has disclosed going-concern uncertainty, and the sector took a significant blow when the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics in August 2024, declining to approve MDMA-assisted therapy for PTSD and requesting an additional Phase 3 trial.

This is a speculative, early-stage offering. It is categorically different from HMH in both maturity and risk profile.

This is Viktor, an AI coworker with its own computer. It lives in Slack, connects to 3,000+ tools, and does all the work: writes the code, handles the API calls, and deploys a live app. One message. Real output.

Try Viktor free.

Brookline Capital Acquisition Corp. II is a Special Purpose Acquisition Company (SPAC), incorporated in the Cayman Islands. It has no operating business, no revenue, and no employees. Its sole purpose is to raise capital through an IPO and use those proceeds to identify and merge with a private company within 24 months.

Management: CEO Patrick A. Sturgeon (Managing Partner, Brookline Capital Markets); Chairman Samuel Wertheimer (Senior Scientific Advisor, Brookline Capital Markets); CFO/President Dimitre Genov (Managing Director, Brookline Capital). Target focus: healthcare and defense technology.

Track record context: In BCAC I, Wertheimer served as Chairman AND CEO while Sturgeon served as CFO. That SPAC merged with Apexigen, Inc. (NASDAQ: APGN) in July 2022. Apexigen was subsequently acquired by Pyxis Oncology in May 2023 for an implied value of approximately $0.64 per share - a roughly 94% decline from the $10.00 SPAC unit price. Apexigen was delisted following the acquisition.

SPAC IPOs are fundamentally different from operating company IPOs. Investors in BCACU are committing $10/unit to a management team they trust to find a compelling acquisition within 24 months. If no deal closes, they receive their money back from trust (plus interest, minus taxes and expenses).

The Brookline team brings genuine healthcare experience and the $10 unit structure provides downside protection. However, the SPAC market has been subdued since 2021, and the BCAC I track record - Apexigen acquired at ~$0.64/share against a $10.00 NAV, a 94% loss - is a serious negative data point investors should weigh carefully.

-Tim